Azitra, Inc. key statistics and ratios
In fiscal 2024, Azitra, Inc. had an operating margin of -146468.5%, debt equal to 0.0% of equity and a current ratio of 3.80. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% | — |
| Net margin | <−999% | <−999% | <−999% | — |
| Free-cash-flow margin | <−999% | <−999% | <−999% | — |
| Return on assets | −149.0% | −183.7% | −143.8% | −176.9% |
| Asset turnover | 0.04 | 0.11 | 0.00 | — |
| Current ratio | 1.86 | 1.58 | 3.80 | 2.83 |
| Debt to equity | — | — | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m |
| R&D as % of revenue | >999% | 531.1% | >999% | — |
| Capital spending as % of revenue | 11.7% | 3.9% | 114.3% | — |
| Quarter | 2023 Q4Dec 2023 | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | — | <−999% | — | — | — | — | — |
| Net margin | <−999% | — | <−999% | — | — | — | — | — |
| Free-cash-flow margin | <−999% | — | <−999% | — | — | — | — | — |
| Current ratio | 1.58 | 2.80 | 0.77 | 5.58 | 3.80 | 1.24 | 1.23 | 2.83 |
| R&D as % of revenue | >999% | — | >999% | — | — | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Creative Medical Technology Holdings, Inc. statistics
- Lyell Immunopharma, Inc. statistics
- AIM Immunotech Inc. statistics
- Ibio, Inc. statistics
- Lisata Therapeutics, Inc. statistics
Head to head: AZTR vs CELZAZTR vs LYELAIM vs AZTR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies